Healthcare industry

Dossier - 10/03/2014

Cancer therapy and cancer diagnostics

Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…

Press release - 21/02/2018

German Cancer Award for Michael Baumann

Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.

Press release - 04/02/2010

World Cancer Day: encouraging the prevention, detection and treatment of cancer

World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.

Press release - 09/03/2011

DKFZ and IBM have signed a collaboration agreement on cancer genome analysis

The International Cancer Genome Project analyzes the complete genomes of thousands of cancer patients. This generates enormous amounts of data. To find those gene segments which are pivotal for cancer development and treatment, intelligent IT systems are needed. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg and IBM have signed a strategic partnering agreement at CeBIT 2011. The aim of the agreement is to…

Harald zur Hausen the long-time chairman and scientific director of the German Cancer Research Centre DKFZ a member of the Helmholtz Society discovered that human papillomaviruses HPV lead to cervical cancer. His discovery led to the development of a vaccine for cervical cancer which is the third most frequent type of cancer in women.

Article - 11/12/2017

KDM4 – an efficient target for the therapy of triple-negative breast cancer

While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…

Article - 25/03/2013

Epigenetics for personalised cancer care for women

Every year in the EU, 45,300 women are diagnosed with ovarian cancer and 330,000 with breast cancer. Ovarian cancer has a mortality rate of around 64% and breast cancer around 27%*. The EU-funded research project EpiFemCare aims at improving cancer detection and subsequent patient care. The research project aims to develop blood tests based on epigenetic DNA modifications, i.e. the methylation of the base cytosine, for the identification of…

“Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting proteins directly to the molecular machinery of a cell’s disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a cancer protein.

Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer.

immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.

Press release - 12/10/2011

Autoimmune Diseases Affect Cancer Risk

In a recently published study, scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have calculated the interrelations between autoimmune diseases and cancer of the digestive tract. They discovered that many autoimmune diseases increase the cancer risk, while others, such as rheumatism, are associated with a significantly lower bowel cancer risk. These differing impacts on cancer risk may be attributable to the…

Vision Zero in oncology - 02/09/2019

Call for a comprehensive master plan for preventing and treating cancer

While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

Article - 09/03/2015

Treating cancer by activating the immune system

Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Cancer cells are dangerous foodies. They metabolise far greater amounts of sugar than healthy cells. Nuclear medicine experts make use of cancer cells craving for sugar since the advent of modern positron emission tomography PET. This has led to an improvement in the quality of cancer treatment.

Press release - 09/06/2011

Blood Clotting and Bowel Cancer Risk

People whose blood clots more easily than normal are more often affected by cancer. Scientists at the German Cancer Research Center have discovered that a number of variants of clotting factor genes have an influence on bowel cancer risk. They found out that carriers of a particular gene variant of clotting factor V have a bowel cancer risk that is six times higher than people who do not have this gene variant.

Press release - 07/04/2009

Ulm Cancer Centre receives €3 million injection

Ulms main cancer research centre has now become one of the eleven German top oncology centres and will receive three million euros in funding from German Cancer Aid over the next three years. The funds will be given for the optimisation and further development of cancer research and treatment.

Article - 22/02/2010

Prevention and early diagnosis of lung cancer

The German Cancer Research Centre and the Thorax Hospital in Heidelberg work very closely together in the diagnosis therapy and prevention of lung cancer. The two institutions have now started a screening intervention study which is the German contribution to major multinational efforts towards a systematic early diagnosis of lung cancer.

Dossier - 05/11/2012

Cancer – basic research, successes and trends

Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer. This…

Article - 26/01/2017

Clinical cancer registration to improve patient treatment and care

Germany records around 500,000 new cases of cancer every year. The number is steadily growing, mainly due to an ageing population that leads to an increased risk of cancer. The German government is planning to establish clinical cancer registries in all German states so that all cancer patients receive the best possible treatment. In Baden-Württemberg, all new cancer cases are already recorded. However, the data are still not as comprehensive as…

Article - 16/02/2015

Therapeutic vaccines against brain tumours

Therapeutic cancer vaccines have the potential to boost the immune system's ability to destroy tumour cells. Cancer researchers around the world are intensively studying the potential of this therapeutic concept and initial positive results have been obtained. Cancer researchers from Heidelberg have developed a vaccine that triggers an immune response against a protein that is mutated in brain cancer. The vaccine, which successfully arrested…

The new cancer medication sorafenib inhibits resistant tumour stem cells in pancreatic cancer and is especially effective when combined with sulforaphane, an organic compound found in broccoli and cauliflower.

Article - 18/05/2015

Parvoviruses can destroy brain tumours

Parvoviruses such as H-1PV have been shown to selectively attack and destroy human cancer cells. However, they are unable to replicate in healthy human cells. A preliminary clinical trial is currently being carried out to assess the suitability of parvoviruses for treating malignant brain cancer. Scientists from the German Cancer Research Center (DKFZ) have now discovered the cause of the selective effect of H-1PV. The finding helps identify…

febit holding gmbh announced today the launch of the first human cancer biochip for HybSelectâ, febit’s highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute.

Press release - 26/05/2014

50 years of research for life without cancer

The German Cancer Research Center (DKFZ) in Heidelberg turns 50 this year. Conducting research on the basic biological mechanisms of cancer, the DKFZ has been instrumental in our current understanding of the development and growth of cancer and has advanced the development of enhanced methods for the prevention, diagnosis and treatment of cancer.